摘要
背景:原发性贲门失弛缓症尚无有效的治疗方法。目的:评价马来酸曲美布汀联合硝酸异山梨酯治疗原发性贲门失弛缓症的临床疗效。方法:54例原发性贲门失弛缓症患者分为治疗组和对照组,治疗组予马来酸曲美布汀200mg tid和硝酸异山梨酯10mg tid,对照组予硝苯地平10mg tid和硝酸异山梨酯10mg tid,疗程均为15d。结果:治疗后,治疗组的总有效率显著高于对照组(P<0.01);两组患者的症状显著改善(P<0.05或P<0.01),其中治疗组吞咽困难和反食的评分显著低于对照组(P<0.05)。结论:马来酸曲美布汀联合硝酸异山梨酯能有效改善原发性贲门失弛缓症的吞咽困难和反食症状,其临床疗效明显优于硝酸异山梨酯联合硝苯地平。
Background： Very effective treatment of achalasia is not available yet. Aims： To evaluate the therapeutic effect of trimebutine maleate combined with isosorbide dinitrate on achalasia. Methods： Fifty-four patients with achalasia were divided into the treatment group and the control group. The treatment group was given trimebutine maleate 200 mg tid and isosorbide dinitrate 10 mg tid, and the control group was treated with nifedipine 10 mg tid and isosorbide dinitrate 10 mg tid. The duration of treatment for both groups was fifteen days. Results： After the treatment, the clinical efficacy of the treatment group was significantly higher than that of the control group （P〈0.01）; the symptoms of the two groups were significantly improved （P〈0.05 or P〈0.01）. And the score of dysphagia and regurgitation of the treatment group were significantly lower than those of the control group （P〈0.05）. Conclusions： Trimebutine maleate combined with isosorbide dinitrate can effectively improve the symptoms of dysphagia and regurgitation of achalasia, and its clinical efficacy is better than isosorbide dinitrate combined with nifedipine.
出处
《胃肠病学》
2007年第10期626-627,共2页
Chinese Journal of Gastroenterology
关键词
食管失弛症
曲美布汀
异山梨酯
硝酸
Esophageal Achalasia
Trimebutine
Isosorbide Dinitrate
